奥雷巴替尼治疗复发伴T315I突变费城染色体阳性急性淋巴细胞白血病的疗效及安全性(附5例)  

Efficacy and safety of Olverembatinib in the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia with recurrent T315I mutation(5 cases)

作　　者：刘倩 卞铁荣 李志远 郭渠莲 邢宏运 LIU Qian;BIAN Tierong;LI Zhiyuan;GUO Qulian;XING Hongyun(Department of Hematology,Affiliated Hospital of Southwest Medical University,Sichuan Luzhou 646000,China;Department of Paediatrics,Affiliated Hospital of Southwest Medical University,Sichuan Luzhou 646000,China)

机构地区：[1]西南医科大学附属医院血液内科,四川泸州646000 [2]西南医科大学附属医院儿科,四川泸州646000

出　　处：《现代肿瘤医学》2024年第13期2420-2424,共5页Journal of Modern Oncology

基　　金：四川省科技支持计划(编号:2022YFS0622);四川省泸州市重点科技项目(编号:2020-SYF-25)。

摘　　要：目的:探索奥雷巴替尼治疗复发伴T315I突变费城染色体阳性急性淋巴细胞白血病(Philadelphia chromosome positive acute lymphoblastic leukemia,Ph^(+)ALL)患者的疗效及安全性。方法:收集该院2021年12月至2023年05月确诊复发伴T315I突变Ph^(+)ALL患者的临床资料,分析复发患者应用奥雷巴替尼后的疗效及安全性。结果:5例复发伴T315I突变Ph^(+)ALL患者应用奥雷巴替尼后,5例患者均达CR,其中3例患者达CMR、MRD(-),2例患者达CR、MRD(+)。所有患者从开始口服奥雷巴替尼到评估达CR的中位时间为37(26~58)天,复发后再次获得CR,到疾病进展或死亡或随访截止的中位PFS时间为92(47~320)天,从患者开始口服奥雷巴替尼到患者死亡或随访截止的中位OS时间为208(115~370)天。截止随访时间,2例患者处于无病存活状态、1例患者因肺部严重感染死亡、2例患者因疾病再次复发死亡。不良反应以骨髓抑制、肝功能、肾功能异常为主,未发生使患者中断治疗的不良反应。结论:奥雷巴替尼治疗伴T315I突变或复合突变的Ph^(+)ALL患者治疗效果良好且不良反应尚可耐受。Objective:To report the efficacy and safety of Olverembatinib in 5 relapsed Ph~+ALL(Philadelphia chromosome positive acute lymphoblastic leukemia) patients with T315I mutation.Methods:The clinical data of relapsed Ph~+ALL patients with T315I mutation diagnosed in this hospital from December 2021 to May 2023 were collected,and the efficacy and safety of Olverembatinib in 5 relapsed patients were analyzed.Results:After treatment with Olverembatinib,all 5 patients achieved CR,3 of them achieved CMR and MRD(-),and the remaining 2 patients achieved CR,MRD(+).The median time to CR was 37 days(range,26~58 days).The median time from CR to disease progression or death or the end of follow-up was 92(range,47~320) days.The median time from the initiation of oral administration of Olverembatinib to death or the end of follow-up was 208(115~370) days.At the end of the follow-up,2 patients were disease-free survival,1 patient died of suspected severe pulmonary infection,and 2 patients died of disease recurrence.The main adverse reactions were bone marrow suppression,abnormal liver function and renal function,and no adverse reactions caused the patient to interrupt treatment.Conclusion:In Ph~+ALL patients with T315I mutation or compound mutation,Olverembatinib showed good efficacy and was not tolerable.

关 键 词：急性淋巴细胞白血病 费城染色体阳性 T315I突变 奥雷巴替尼 

分 类 号：R733[医药卫生—肿瘤]